




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/94, 209/96, 295/06, 295/08, 295/14, 333/58, 333/50, A61K 31/495	A1	(11) International Publication Number: WO 98/08835 (43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/IB97/00978 (22) International Filing Date: 8 August 1997 (08.08.97) (30) Priority Data: 60/024,797 26 August 1996 (26.08.96) US (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BUTLER, Todd, William [US/US]; 113 Witter Road, Salem, CT 06420 (US). FLIRI, Anton, Franz, Joseph [AT/US]; 120 McKinley Avenue, Norwich, CT 06360 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: SPIROCYCLIC DOPAMINE RECEPTOR SUBTYPE LIGANDS**(57) Abstract**

This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R¹ through R⁶ are defined as in the specification. These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 **Spirocyclic Dopamine Receptor Subtype Ligands** **Background to the invention**

 The present invention pertains to novel pharmacologically active trans-piperazin-1-yl-spiro[cyclohexane-1,1'-isobenzofuran] derivatives that are dopamine receptor subtype ligands having a preference for the D4-dopamine receptor. These compounds
10 exhibit central dopaminergic activity, as defined below, and are useful in the treatment and/or prevention of disorders of the dopamine system, including schizophrenic and schizoaffective disorders, akinesia, dementia, Parkinson's disease, nausea, bipolar disorders, emesis, tardive dyskinesia, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, hyperprolactemia and amenorrhoea.

15 The biological activity of only a few spirocyclic cyclohexane systems has been described. For example, in United States 3,932,425, United States Patent 4,025,558 and United States Patents 4,010,201, D. Lednicer refers to a series of spirocyclic cyclohexylamine derivatives that possess tranquilizing activity and are consequently useful in anxiety and schizophrenia and can be administered to reduce aggressive
20 behavior and lower blood pressure. In United States Patent, 5,403,846, John J. Baldwin et al. refer to a series of spirocyclic benzopyrano cyclohexylamine derivatives that were studied for potassium channel blocking activity and found to exhibit type III antiarrhythmic activity. In World Patent Application PCT/US95/05940, the same inventor, John J. Baldwin, refers to a series of spirocyclic dihydrobenzopyrano derivatives as
25 constituting part of a combinatorial chemical library that contains ligands for potassium channels, adrenergic receptors, dopamine receptors and sigma-opioid receptors, and also refers to the use of this library for identifying biologically active agents such as, for example, inhibitors for carbonic acid anhydrase useful for treatment of glaucoma. Lawrence L. Martin describes, in J. Med. Chem., **24**, pg. 617-621, 1981, the synthesis
30 of a series of spiro isobenzofuran derivatives containing dialkylamino substituents and refers to the activity of these agents as centrally acting serotonergic agents. Similarly, William E. Parham describes, in J. Org. Chem., **41**, pg. 2628-2633, 1976, the synthesis of a series of spiro [isobenzofuran- (3H), 4'piperidine derivatives and biological activities that suggest their utility as antidepressant and antipsychotic agents. United States
35 Patent 5,352,678 refers to a series of dopaminergic cyclohexane derivatives and their use as antiischemic and antipsychotic agents.

-2-


United States Patent 5,352,678, which issued on October 4, 1994, refers to dopaminergic cyclohexane derivatives and to their utility as antiischemic and antipsychotic agents.

International Patent Application WO 94/19367, which was published on September 1, 1994, refers to spiropiperidine derivatives and to their ability to increase endogenous hormone levels.

Thus, it is generally known that dopamine receptors are important for many functions in the animal body. For example, altered functions of these receptors are thought to participate in the genesis of psychosis, drug addiction, compulsive disorders, bipolar disorders, vision, emesis, sleep, feeding, learning, memory, sexual behavior, regulation of immunological responses and blood pressure. Since these receptors control a great number of pharmacological events and, on the other hand, not all of them are presently known, it is possible that compounds acting preferentially on dopamine receptor subtypes, for example, on the D4 dopamine receptor, will exert a wide range of therapeutic effects in humans.

Summary of the Invention

This invention relates to compounds of the formula



wherein a is oxygen, CH_2 , $\text{C}(\text{CH}_3)_2$, NR^{10} , sulfur, SO or SO_2 ;

b is oxygen, CH_2 , $\text{C}=\text{O}$, $\text{C}=\text{NR}^{11}$, $\text{C}=\text{NOH}$, SO_2 , sulfur, SO, $\text{C}=\text{NO}(\text{C}_1\text{-C}_5)\text{alkyl}$ or CR^7R^8 ;

-3-

each of R^1 through R^6 is selected, independently, from hydrogen, halogen (e.g., chloro, fluoro, bromo or iodo), trifluoromethyl, cyano and hydroxy, or R^7 and R^8 together can be $C(=O)NH_2$ or $C(=O)N(C_1-C_4)alkyl$, with the proviso that neither R^7 nor R^8 can be halo when a is oxygen, NR^{11} , sulfur, SO or SO_2 ; and

5 each of R^{10} and R^{11} is selected, independently, from hydrogen, benzyl and $(C_1-C_6)alkyl$;

and the pharmaceutically acceptable salts of such compounds.

Preferred compounds of the formula I are those wherein a is oxygen, b is CH_2 , each of R^1 , R^4 and R^5 is hydrogen, and each of R^2 , R^3 and R^6 is selected,
10 independently from hydrogen, cyano, chloro and fluoro.

Other more specific embodiments of this invention include:

- (a) compounds of the formula I wherein a is oxygen;
- (b) compounds of the formula I wherein a is oxygen and b is CH_2 ;
- (c) compounds of the formula I wherein a is oxygen, b is CH_2 and each of R^1 , R^4
15 and R^5 is hydrogen;
- (d) compounds of the formula I wherein a is oxygen, b is CH_2 , each of R^1 , R^4 and R^5 is hydrogen and R^3 is fluoro, cyano or chloro;
- (e) compounds of the formula I wherein a is oxygen, b is CH_2 , each of R^1 , R^4 and R^5 is hydrogen and each of R^2 , R^3 and R^6 is selected, independently, from
20 hydrogen, fluoro, cyano and chloro; and
- (f) compounds of the formula I wherein a is oxygen, b is CH_2 , each of R^1 , R^4 and R^5 is hydrogen, and R^2 and R^3 are selected, independently, from fluoro, cyano and chloro.

The compounds of formula I above may contain chiral centers and therefore
25 may exist in different enantiomeric forms. This invention relates to all optical isomers and all other stereoisomers of compounds of the formula I and mixtures thereof.

This invention also relates to a pharmaceutical composition for treating or preventing a condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar
30 disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising an amount of a compound of the formula I, or pharmaceutically acceptable salt thereof,

-4-

that is effective in treating or preventing such condition, and a pharmaceutical acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or pharmaceutically acceptable salt thereof, that is effective in treating or preventing such condition.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising a dopaminergic effective amount of a compound of the formula I, or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising administering to said mammal a dopaminergic effective amount of a compound of the formula I, or pharmaceutically acceptable salt thereof.

This invention also relates to a pharmaceutical composition for treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering (i.e., increasing or decreasing) dopamine mediated neurotransmission in a mammal, including a human, comprising a dopaminergic effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

This invention also relates to a method of treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering (i.e., increasing or decreasing) dopamine mediated neurotransmission in a mammal, including a human, comprising administering to said mammal a dopaminergic effective
5 amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from
10 neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising a D4 receptor binding effective amount of a compound of the formula I, or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a
15 condition selected from psychosis, affective psychosis, nonorganic psychosis, personality disorders, dysphoric mania, schizophrenic and schizoaffective disorders, bipolar disorders, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, including a human, comprising an
20 administering to said mammal a D4 receptor binding effective amount of a compound of the formula I, or pharmaceutically acceptable salt thereof.

This invention also relates to a pharmaceutical composition for treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, including
25 a human, comprising a D4 receptor binding effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

This invention also relates to a method of treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering
30 dopamine mediated neurotransmission in a mammal, including a human, comprising administering to said mammal a D4 receptor binding effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The term "dopaminergic effective amount", as used herein, refers to an amount of a compound sufficient to inhibit the binding of dopamine to a dopamine receptor with the effect of altering (i.e., increasing or decreasing) dopamine mediated neurotransmission.

5 The compounds of formula I that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of those compounds of formula I that are basic in nature are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride,
10 hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-
15 3-naphthoate)] salts.

This invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I.

The term "one or more substituents", as used herein, includes from one to the maximum number of substituents possible based on the number of available bonding
20 sites.


The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

The term "alkoxy", as used herein, unless otherwise indicated, refers to radicals
25 having the formula -O-alkyl, wherein "alkyl" is defined as above.

Detailed Description of the Invention


Compounds of the formula I and their pharmaceutically acceptable salts may be prepared as described below. In the reaction scheme and discussion that follows, a, b, R¹ through R¹¹ and structural formula I are defined as above.

-7-

SCHEME 1


-8-

SCHEME 2



-9-


SCHEME 3




-10-

SCHEME 3 (continued)

VIII




IX



II

-11-

SCHEME 4

-12-

SCHEME 4 (continued)


X



5


10

15



IV

-13-

SCHEME 5

-14-


SCHEME 5 (continued)

XIII

5



10




15

XIV



20



25


XV



30


II

-15-

SCHEME 6

-16-


SCHEME 7




-17-

SCHEME 7 (continued)

XIX



XX



XXI

I

Schemes 1 and 2 illustrate methods of synthesizing compounds of the formula I.

Referring to scheme 1, a compound of the formula II is reacted with a compound of the formula III to form a compound of the formula I. This reaction is generally carried out in an inert solvent at a temperature from about 0°C to about 150°C, preferably from about 0°C to about the reflux temperature of the solvent. Suitable solvents include water, cyclic and acyclic mono and dialkylamides (e.g., N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidinone (NMP), formamide and acetamide), (C₁-C₄)alkanols, halogenated hydrocarbon solvents (e.g., methylene chloride, chloroform and dichloroethane), acyclic and cyclic alkyl ethers (e.g., diisopropyl ether and tetrahydrofuran (THF)) and mixtures of two or more of the foregoing solvents.

Referring to scheme 2, a compound of the formula V, wherein Y is bromine, chlorine or iodine and L is a suitable group such as O-lithium, O-potassium, O-sodium, O-magnesium, -O-(C₁-C₄)alkyl, N-Metal-phenyl wherein Metal is lithium, sodium, potassium or magnesium, -O-tri(C₁-C₄)alkylsilyl or -NH-phenyl, is cooled to about -80°C and converted into the corresponding compound wherein Y is lithium, potassium, sodium or magnesium, preferably lithium, using conventional methods (e.g., by addition of n-butyl lithium, t-butyl lithium or 2-methylpropyl lithium). After addition of the appropriate reagent, the reaction mixture is allowed to warm to room temperature. The resulting mixture containing the organometallic product of formula V is then cooled again to about -80°C and a compound of the IV is added to it, as depicted in the scheme, to form an intermediate of the formula VI, wherein L' and LG'' are the same or different and are selected from -OH, -O-CH₂-O-(C₁-C₄)alkyl, -O-tri(C₁-C₄)alkylsilyl, -NH₂, -NH-phenyl, -N-(C₁-C₄)alkyl, -SH, -S-trityl and -N-benzyl. The intermediate of formula VI can be converted into the corresponding compound of formula I via a ring closure step, as described below. Both the formation of the organometallic compound of formula V and the reaction of such compound with a compound of the formula IV are typically carried out in inert organic solvents such as cyclic or acyclic alkyl ethers (e.g., diisopropyl ether or THF) or mixtures of two or more such solvents.

The intermediate of formula VI can either be isolated or converted in situ into the desired compound of formula I. If the reaction mixture containing the intermediate is quenched with water, the intermediate will not react further and will be able to be isolated from the mixture by conventional methods. If, however, the mixture is refluxed

with hydrochloric acid or another strong acid (e.g., sulfuric acid, nitric acid or sulfurous acid) at a temperature from about 0°C to about 150°C, preferably at the reflux temperature, and contains an inert solvent selected from cyclic and acyclic mono and dialkylamides, acyclic alkyl ketones, (C₁-C₄)alkanols and mixtures of two or more such solvents, ring closure will occur, producing a compound of the formula I.

Alternate ring closure methods that can be used to form compounds of the formula I from the corresponding intermediates of formula VI are referred to by Martin, L.L., J. Med. Chem., 24, 617-621 (1981). This article is incorporated herein by reference in its entirety.

Scheme 3 illustrates a method of preparing the starting materials of formula II that are used in scheme 1. This method involves reacting the compound having formula VII with an organometallic compound of the formula V wherein Y is lithium, potassium, sodium or magnesium, preferably lithium. This reaction is typically carried out in a similar manner (and using similar solvents and conditions) to the reaction depicted in scheme 2 which forms the intermediate of formula VI. Thus, a compound of the formula V, wherein Y is chloro, bromo or iodo and L is defined as above, is cooled to a temperature of about -80°C and converted, using conventional techniques, into the corresponding compound wherein Y is lithium, potassium, sodium or magnesium, preferably lithium, and then allowed to warm to room temperature. The reaction mixture containing the organometallic product of formula V is then cooled again to about -80°C and a compound having formula VII is added to it to form an intermediate of the formula VIII, after which the mixture is again allowed to warm to about room temperature. As was the case for the process depicted in scheme 2, quenching the reacting mixture with water will prevent further reaction of the intermediate and allow it to be isolated, while refluxing with a strong acid will cause closure of the a-b-containing spirocyclic ring and hydrolytic removal of the ketal group to form the desired compound of formula II.

Compounds of the formula II wherein a is oxygen and b is oxygen or CH₂ can be formed from the corresponding compounds of the formula VIII wherein L' and L'' are hydroxy by treating the latter compound with a mineral acid (e.g., hydrochloric acid, phosphoric acid, sulfuric acid, perchloric acid, or nitric acid) in a mixture containing an inert solvent selected from cyclic and acyclic mono and dialkylamides, cyclic and acyclic mono and dialkylethers, acyclic alkyl ketones, (C₁-C₄)alkanols and mixtures of

-20-

two or more such solvents. The reaction temperature can range from about 0°C to about 150°C, and is preferably about the reflux temperature of the reaction mixture.

The spirocyclic ring of compounds of the formula II can be formed, alternatively, by reacting a compound of the formula VIII, wherein b is CH₂ and L' is hydrogen, with
5 N-bromo, N-chloro or N-iodo succinimide in the presence of a radical generating agent (e.g., dibenzoyl peroxide or ultraviolet light). The corresponding compound of formula II is then formed by removing the ketal protecting group in intermediary products under acidic conditions.


The spirocyclic ring of compounds of the formula II wherein b is CH₂ or oxygen
10 and a is NH, N(C₁-C₄)alkyl or S can be formed, alternatively, from compounds of the formula VIII wherein b is CH₂ or oxygen and L' and L'' are selected, independently, from O-sulfonyl, -(C₁-C₆)alkyl, -O-sulfonylphenyl, halo and like substituents, by treating the latter compounds with the appropriate lower alkylamine, ammonia, benzylamine or sodium sulfide. This reaction is generally carried out in an inert organic solvent
15 selected from cyclic and acyclic mono and dialkylamides, cyclic and acyclic mono and dialkylethers, cyclic and acyclic alkylketones, (C₁-C₄)alkanols and mixtures containing two or more such solvents, at a temperature from about 0°C to about 150°C, preferably at the reflux temperature.

Another process for the preparation of compounds of formula II wherein b is
20 CH₂ is illustrated in schemes 5 and 6 and described below. Starting with compounds of the formula XIII

25

30


-21-



XIV

such compounds can be converted into compounds of the formula II in the presence of a trialkyltin-hydride such as, for example, tributyltinhydride and a radical generating reagent such as, for example, azo-bis-(isobutyronitrile) and by removing the ketal protecting group in the intermediary products under acidic conditions. This conversion can be carried out in a solvent such as benzene or toluene at a temperature ranging from about 25°C to about the reflux temperature. When protecting groups such as, for example, acetals are used, it may be convenient to remove such groups under acidic procedures. Similarly, other commonly used protecting groups may be introduced and removed using methods generally known to those skilled in the art.

Compounds of formula XIV may be prepared from the corresponding compounds having the general structure XIII




XIII

-22-


The conversion of compounds having the general structure XIII into compounds of the formula XIV can be conveniently carried out in an inert organic solvent such as methylene chloride or chloroform, at temperature ranging from about -25°C to about the reflux temperature, in the presence of an (C₁-C₄)alkyl-sulfonylchloride and an acid acceptor such as an alkali carbonate, a tertiary amine or a similar reagent.

Intermediates of the formula XIII wherein, for example, b is oxygen, sulfur or amino, may be prepared by reacting compounds of the formula XII



XIII

wherein L''' is bromo and b is hydroxy, mercapto or amino with a compound of the formula XI



XI

This reaction can be conveniently carried out in an inert organic solvent such as benzene, toluene, xylene, pyridine, collidine, methylene chloride or chloroform, at a temperature ranging from about 25°C to about the reflux temperature of the reaction mixture, in the presence of an acid acceptor such as an alkali carbonate, a tertiary amine or a similar reagent.

Compounds having the general formula XII are either commercially available or known in the literature. Compounds of the formula XI can be prepared from commercially available cyclohexanone derivatives and trialkylsulfonium derivatives using known methods such as those described by Rene Gree, Synthetic Communication,
5 15(8), 749-757 (1985).

Compounds of the formula V can be prepared from commercially available materials by known methods, e.g., as described by L.L. Martin in J. Med. Chem., 24, 617-621, 1981, referred to above. This reference is incorporated herein by reference in its entirety.

10 Scheme 4 illustrates the preparation of compounds of the formula IV, which are used as starting materials in the process depicted in scheme 2. Referring to scheme 4, a compound of the formula VII is first reacted with a compound of the formula III to form a compound of the formula X. This reaction is generally carried out using the same solvents and conditions described above for the reaction depicted in scheme 1
15 (i.e., the formation of compounds of the formula I from the reaction of compounds of the formulae II and III). Thus, compounds embraced in general formula X may be prepared by reacting compounds having the general formula III with the cyclohexanone derivative of formula VII in a solvent selected from water, cyclic and acyclic mono and dialkylamides, (C₁-C₄)alkanols, halogenated solvents, acyclic and cyclic alkylethers and
20 mixtures of two or more such solvents at temperatures ranging from 0°C to about 150°C, preferably from about 0°C to about the reflux temperature of the reaction mixture.

Compounds of the general formula IV may be prepared by hydrolysing compounds with general formula X with an aqueous mineral acid in a solvent selected
25 from cyclic and acyclic mono and dialkylamides, cyclic and acyclic mono and dialkylethers, cyclic and acyclic alkylketones, (C₁-C₄) alkanols and mixtures of two or more such solvents at temperatures ranging from about 0°C to about 150°C, preferable at the reflux temperature of the mixture.

Compounds with general formula III may be prepared by reacting piperazine
30 derivatives with an appropriate aryl transferring group in a solvent selected from cyclic and acyclic mono and dialkylamides, (C₁-C₄) alkanols, cyclic and acyclic alkylethers, cyclic and acyclic alkylesters, cyclic and acyclic alkylketones, pyridine derivatives, halogenated solvents and mixtures of two or more such solvents at temperatures

ranging from about 0°C to about 150°C, preferably from about 0°C to about the reflux temperature of the mixture. Addition of acid acceptors such as an alkali carbonates, tertiary amines or similar reagents as well as the addition of dehydrating reagents may be useful.

- 5 An alternate method of preparing compound of the formula I is illustrated in Scheme 7.

Referring to Scheme 7, a compound of formula XIX may be prepared by reacting a compound of formula XVIII, wherein PG is a nitrogen protecting group, with compound of the formula II, in water or an inert organic solvent such as those selected
10 from polychlorinated C₁-C₂ alkanes, cyclic and acyclic mono and dialkylamides (e.g., N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidinone (NMP), formamide and acetamide), (C₁-C₄)alkanols, halogenated hydrocarbon solvents (e.g., methylene chloride, chloroform and dichloroethane), acyclic and cyclic alkyl ethers (e.g., diisopropyl ether and tetrahydrofuran (THF)) and mixtures of two or more of the
15 foregoing solvents, at temperatures ranging from about 0°C to about 150°C, preferably at 0°C or the boiling point of the solvent mixture.

Compounds of formula XX can then be prepared by deprotecting a compound of general formula XIX according to a method suitable to the protecting group selected. For example, when the protecting group is benzyl, trityl, benzhydryl or carbobenzyloxy,
20 deprotection may be accomplished by hydrogenation in presence of a catalyst, in a solvent in selected from water and inert organic solvents, such as those selected from cyclic and acyclic mono and dialkylamides, (C₁-C₄) alcohols, acyclic and cyclic alkylethers and mixtures of two or more of the foregoing solvents, at temperatures ranging from about 0°C to about 150°C. When the protecting group is
25 tertiarybutoxycarbonyl or benzyloxycarbonyl, deprotection may be accomplished by treating a compound of formula XIX with an acid in water or an inert organic solvent such as those selected from cyclic and acyclic mono and dialkylamides, (C₁-C₄) alcohols, acyclic and cyclic alkylethers, and mixtures of two or more of the foregoing solvents, at temperatures ranging from about 0°C to about 150°C.

- 30 Compounds of general formula I can be prepared by reacting a compound of the formula XX with an appropriate aryl transferring group in water or an inert organic solvent, such as those selected from cyclic and acyclic mono and dialkylamides, C₁-C₄ alcohols, cyclic and acyclic alkylethers, cyclic an acyclic alkylesters, cyclic and acyclic

alkyletones, pyridine derivatives, halogenated hydrocarbons, and mixtures of two or more of the foregoing solvents, at temperatures ranging from about 0°C to 150°C, preferable from about 0°C or the to the reflux temperature of the solvent mixture. Addition of acid acceptors such as an alkali carbonates, tertiary amines or similar reagents as well as the addition of dehydrating reagents may be useful.

Compounds embraced in general formula III are either commercially available or can be prepared by reacting known piperazine derivatives with aryl transferring reagents. Thus, these reactions can be conveniently carried out in water or an inert organic solvent such as those selected from alcohols, pyridine, cyclic and acyclic alkylketones, cyclic and acyclic alkylesters, cyclic and acyclic alkylethers, cyclic and acyclic mono and dialkylamides, and mixtures of two or more of the foregoing solvents, at temperatures ranging from -80°C to 150°C. Addition of acid acceptors such as an alkali carbonates, tertiary amines or similar reagents, as well as the addition of dehydrating reagents, may be useful.

The reaction of arylmetal compounds with cyclohexanone derivatives is preferably performed at a temperature from about -80°C to about 0°C. All other reaction steps are preferable carried out at temperatures ranging from about 0°C to about the reflux temperature of the solvent. When ketone protecting groups such as acetals are employed, it may be convenient to remove these groups using acidic reaction conditions. Similarly, other commonly used protecting groups may be introduced and removed according to methods generally known to someone skilled in the art.

The preparation of other compounds of the formula I not specifically described in the foregoing discussion section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

In each of the reactions discussed or illustrated in schemes 1 to 7 above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 4 atmospheres are generally acceptable, and ambient pressure, i.e., about 1 atmosphere, is preferred as a matter of convenience.

The novel compounds of the formula I and their pharmaceutically acceptable salts (hereinafter "the therapeutic compounds of this invention") are useful as dopaminergic agents, i.e., they possess the ability to alter dopamine mediated neurotransmission in mammals, including humans. They are therefore able to function

as therapeutic agents in the treatment of a variety of conditions in mammals, the treatment or prevention of which can be effected or facilitated by an increase or decrease in dopamine mediated neurotransmission. Such conditions include psychosis, affective psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, emesis, nausea, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, hyperdermia and amenorrhea.

The compounds of the formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

The therapeutic compounds of this invention can be administered orally, transdermally (e.g., through the use of a patch), parenterally or topically. Oral administration is preferred. In general, these compounds are most desirably administered in dosages ranging from about 0.01 mg up to about 250 mg per day, although variations may occur depending on the weight and condition of the person being treated and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

-27-

The therapeutic compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the two routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic compounds of this invention
5 can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic
10 organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and
15 preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this
20 connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene
25 glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection
30 purposes. The oily solutions are suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

-28-

Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

5 The D4 dopaminergic activity of the compounds of the present invention may be determined by the following procedure.

 The determination of D4 dopaminergic activity has been described by Van Tol et al., Nature, vol. 350, 610 (London, 1991). Clonal cell lines expressing the human dopamine D4 receptor are harvested and homogenized (teflon pestle) in a 50 mM
10 Tris.HCl (pH 7.4 at 4°C) buffer containing 5 mM EDTA, 1.5 mM calcium chloride (CaCl₂), 5 mM magnesium chloride (MgCl₂), 5mM potassium chloride (KCl) and 120 mM sodium chloride (NaCl). The homogenates are centrifugated for 15 min. at 39,000 g, and the resulting pellets resuspended in a buffer at a concentration of 150-250 µg/ml. For saturation experiments, 0.25 ml aliquots of tissue homogenate are incubated in
15 duplicate with increasing concentrations of [³H] Spiperone (70.3 Ci/mmol; 10-3000 pM final concentration) for 30-120 minutes at 22°C in a total volume of 1 ml. For competition binding experiments, assays are initiated by the addition of 0.25 ml of membrane and incubated in duplicate with the indicated concentrations of competing ligands (10⁻¹⁴-10⁻¹³ M) and [³H]Spiperone (100-300 pM) in either the absence or
20 presence of 200 µM GPP(NH)^p (5'/guanylylimidodiphosphate), where indicated, for 60-120 min at 22°C. Assays are terminated by rapid filtration through a Titertek cell harvester and the filters subsequently monitored for tritium as described by Sunahara, R.K. et al., Nature, 346, 76-80 (1990). For all experiments, specific [³H]Spiperone binding is defined as that inhibited by 1-10 µM (+) Butaclamol or 1 µM Spiperone.
25 Both saturation and competition binding data are analyzed by the non-linear least square curve-fitting program Ligand run on a digital Micro-PP-11 as described by Sunahara et. al.

 The present invention is illustrated by the following Examples. It will be understood, however, that the invention is not limited to the specific details of the
30 Examples.

EXAMPLE 1

trans, Piperazine, 1-[4-fluorophenyl]-4-spiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl), hydrochloride

0.130 g (0.643mmol, 1.0 equiv.) of 3'H-Spiro[cyclohexane-1,1'-isobenzofuran]-4-one was added to 4 ml 1,2 dichloroethane. 0.127g (0.707mmol, 1.1 equivalents (equiv.) 4-fluorophenyl piperazine was then added along with 2.0 equiv. (0.273g) sodium triacetoxyborohydride. The mixture was stirred at room temperature for 12 hours. To this mixture was added 2N sodium hydroxide (NaOH) 1ml and the mixture was stirred for 1 hour and then extracted with ethyl acetate. The residue obtained after removal of solvents was purified via Flash Chrom.: stationary phase SiO₂, eluent 10% EtOAc/hexane. Fractions containing the cis and trans isomers, were collected. The residues obtained after removal of solvents were dissolved in ethanol (EtOH) and treated with a saturated solution of hydrochloric acid (HCl) in EtOH. The white precipitates obtained were filtered and dried under vacuum. Rf¹ is the isomer carrying the phenyl group and piperazine group in equatorial/axial positions (hereinafter denoted as trans).

C₂₃H₂₇FN₂O, FW=366.48 (FREEBASE), 402.93 (HCl salt).

GC-MS10.33 Min., M⁺ 366.

MP >250°C (HCl).

¹H NMR (250 MHz, CDCl₃) δ 1.5-1.8 (2H, br m), 1.6-2.0 (6H, br m), 2.45 (1H, m), 2.7 (4H, m), 3.1 (4H, m), 6.8-7.4 (8H, aromatic).

¹³C NMR (63 MHz, CDCl₃) δ 24.93, 34.17, 45.11, 49.55, 50.53, 61.11, 83.34, 109.91, 115.29, 115.64, 117.63, 117.75, 120.16, 124.60, 128.19, 135.06, 148.01, 159.87

EXAMPLE 2

trans, 2-Fluoro-4-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-benzonitrile

0.493 g, 2.4 mmol of 3'H-Spiro[cyclohexane-1,1'-isobenzofuran]-4-one was added to 6.0ml 1,2 dichloroethane and 1.0 equiv. of 1(4-cyano-3-fluorophenyl) piperazine (0.5g, 2.43 mmol). Sodium triacetoxyborohydried 2.0 equiv. (1.03 g, 4.87 mmol) was added last. Contents of the flask were stirred at room temperature for 18 hours and poured into water (H₂O) and extracted with methylene chloride (CH₂Cl₂). The organic layer was dried with magnesium sulfate (MgSO₄) and concentrated down, leaving a solid. [On a small scale (< 3 grams) the product is dried and the cis/trans

-30-

isomers purified by flash chromatography. On larger scale, the products will precipitate on a flash column using EtOAc/hexane]. The mixture of cis/trans isomers were added to a large flask containing EtOH. The EtOH was refluxed until the compounds are solubilized. Upon cooling, one of the isomers began to precipitate from the EtOH before the other isomer. This procedure was repeated to further purify the isomers. The isomer with the highest R_f value (least polar) was trans 2-fluoro-4-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-benzonitrile.

$C_{24}H_{27}FCIN_3O$, (HCl), $C_{25}H_{30}FN_3O_4S$ (mesylate).

FW= 391.49 (freebase), 427.95 (HCl), 487.60 (mesylate).

10 mp: Freebase 198°C, HCl >250°C, mesylate=263°C (decomposition) GC-MS 10.72 Min., M+391.

1H NMR ($CDCl_3$ 400 MHz) δ 1.6 (m, 2H), 1.9 (m, 4H), 2.0 (m, 2H), 2.4 (s, 1H), 2.69 (m, 4H), 3.37 (m, 4H), 5.0 (s, 2H), 6.63 (m, 2H), 7.2 (m, 4H), 7.4 (m, 1H).

15 ^{13}C NMR ($CDCl_3$ 100 MHz) δ 24.7, 33.0, 47.3, 49.4, 58.9, 70.5, 86.7, 100.4, 100.6, 109.7, 115.4, 121.1, 121.2, 127.1, 127.4, 133.9, 139.2, 146.2, 155.2, 155.3, 166.1.

Analysis calculated for $C_{24}H_{26}FN_3O$ HCl: C, 67.36; N, 9.82. Found: C, 67.04; H, 6.48; N, 9.94.

EXAMPLE 3

20 trans, Spiro[(cyclohex-1,3'-isoindolin)-1'-one]-4-yl-4-(4-fluoro-phenyl)-piperazine dihydrochloride

1-(4-Fluorophenyl)piperazine (0.75g, 4.14 mmol), sodium triacetoxymethylborohydride (1.76g, 8.30 mmol), and Spiro[cyclohexane-1,1'-[1H]isoindole]-3',4(2'H)-dione (0.90g, 4.18 mmol) were dissolved in 1,2-dichloroethane (100 mL) and stirred overnight at ambient temperature. The reaction was concentrated and stirred with 1N NaOH and ethyl acetate (50 mL each) for 1 hour. The organic phase was washed with brine, dried over magnesium sulfate and concentrated onto silica gel. Flash column chromatography on silica gel (1.5 " x 4") was performed. The column was flushed with 2500 mL 50% ethyl acetate/ hexane and the trans diastereomer was removed using 750 mL 75% ethyl acetate/ hexane as eluent. Concentration gave a white solid (0.317g), which was further purified by recrystallization from ethyl acetate/methylene chloride to yield 0.135 g (9%). The hydrochloride salt was prepared in absolute ethanol with HCl gas to give a white solid, trans-, spiro[(cyclohex-1,3'-isoindolin)-1'-one]-4-yl-4-(4-fluoro-phenyl)-piperazine.

-31-

mp=238.5-242°C.

Analysis calculated for $C_{23}H_{26}FN_3O \cdot 2HCl \cdot 2.5H_2O$: C, 55.54; H, 6.28; N, 8.44.

Found: C, 55.49; H, 6.15; N, 8.24.

EXAMPLE 4

5 trans-1-(3',3'-Dimethyl-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-phenyl)-piperazine dihydrochloride

3',3'-dimethyl-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one (0.95 g, 3.46 mmol), 1-(4-fluorophenyl)piperazine (0.63g, 3.50 mmol) and sodium triacetoxyborohydride (1.48 g, 6.98 mmol) were stirred in 1,2-dichloroethane overnight.

10 The reaction was concentrated and the residue stirred 1 hour with 75 mL each ethyl acetate and 1N sodium hydroxide. The organic phase was washed with water and brine, dried over magnesium sulfate and concentrated onto silica gel. The products were separated by flash chromatography on silica gel (1.5"x 4"). Elution with 25 % ethyl acetate/ hexane (500 mL) gave the trans diastereomer of 1-(3',3'-dimethyl-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-phenyl)-piperazine as a white solid
15 (0.32g, 23%), which was converted to the dihydrochloride salt in ethanol with HCl gas.

mp >260°C.

Analysis calculated for $C_{25}H_{31}FN_2O \cdot 2HCl \cdot 0.25H_2O$: C, 63.62; H, 7.15; N, 5.94.

Found: C, 63.50; H, 6.92; N, 5.59.

20 **Examples for the preparation of intermediates with general structure II**

EXAMPLE 5

3'H-Spiro[cyclohexane-1,1'-isobenzofuran]-4-one

0.64 g (2.62 mmol) of 8-(2-Hydroxymethyl-phenyl)-1,4-dioxo-spiro[4.5]decan-8-ol was added to 80% trifluoroacetate (TFA) 2.5 ml. The mixture was stirred at room
25 temperature for 5 hours. Rotary evaporation of the TFA left thick brown oil. The oil was dissolved in 2.0 ml of EtOAc and washed first with 1N NaOH and then with H₂O. The organic layer was dried with MgSO₄ and concentrated, leaving a thick yellow oil. Hexane/ether (2:1) was added and the sides of the flask were scratched. A precipitate began to form. 0.23 Grams of 3'H-Spiro[cyclohexane-1,1'-isobenzofuran]-4-one were
30 obtained, 44% yield.

-32-

^1H NMR (CDCl_3 , 400 MHz) δ 2.16-2.11 (m, 4H), 2.41-2.35 (m, 2H), 2.95-2.83 (m, 2H), 5.16 (s, 2H), 7.11-7.08 (m, 1H), 7.33-7.23 (m, 3H).

^{13}C NMR (CDCl_3 , 100 MHz) δ 36.98, 37.92, 71.14, 85.14, 120.5, 121.31, 127.52, 127.97, 138.8, 144.37, 211.55

5 Analysis calculated for $\text{C}_{24}\text{H}_{26}\text{FN}_3\text{O HCl}$: C, 77.20; H, 6.98. Found: C, 77.21; H, 7.06;

EXAMPLE 6

8-[2-(1-Hydroxy-1-methyl-ethyl)-phenyl]-1,4-dioxo-spiro[4.5]deca-8-ol

(1.37g, 4.69 mmol) and boron trifluoride diethyl etherate (1.2 mL, 9.76 mmol, 2 equiv.) were stirred overnight at ambient temperature in benzene (75mL). Water (25 mL) was added and the reaction was stirred for 45 min. The organic phase was washed with saturated sodium bicarbonate and brine, and then dried over magnesium sulfate and concentrated to a waxy yellow solid (1.13g). This material was partially purified by flash chromatography (1.5"x4" silica gel, 250 mL 10% ethyl acetate/hexane) to yield 15 0.95g (88%) of 3',3'-dimethyl-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one as a light yellow solid, which was used in the next reaction without further purification.

EXAMPLE 7

Spiro[cyclohexane-1,1'-benzofuran]-4-one

The ketal protecting group of 3'H-spiro[cyclohexane-1,1'-benzofuran]-4-one 20 diethylacetal, was removed by dissolving it in 5ml dioxane, adding 2ml 1 N HCl and refluxing the mixture for four hours. The mixture was concentrated to dryness, EtOAc was added, the mixture was washed with water, and the organic layer was dried with sodium sulfate. The residual white solid, 0.130 g, consisted of 3'H-spiro[cyclohexane-1,1'-benzofuran]-4-one.

25 GC-MS FW=202.25.

1 peak at 3.770 min.

^1H NMR (250 MHz, CDCl_3) δ 2.12-2.19 (4H, m), 2.49-2.57 (4H, m), 4.56 (2H, s), 6.8-7.2 (4H, aromatic).

^{13}C NMR (63 MHz, CDCl_3) δ 159.26, 133.37, 128.81, 122.75, 120.80, 110.04, 30 80.11, 45.23, 38.29, 36.18.

EXAMPLE 8Spiro[cyclohexane-1,1'-[1H]isoindole]-3',4(2'H)-dione

Crude Spiro-[(cyclohexan-1,3'-isoindolin)-1'-one]-4-one (1.3g, 5.0 mmol) was added to ice cold perchloric acid (30 mL) and stirred for 2 hours. The reaction was made basic by careful addition of sodium hydroxide pellets (added slowly to keep the temperature low). The basic mixture was extracted with ethyl acetate (3 x 60 mL) and the combined extracts were washed with water and brine, dried over MgSO₄ and concentrated onto silica gel. Purification by silica gel flash chromatography using 50% ethyl acetate/hexane gave (0.95g, 88%) of the desired spirocyclohexanone-benzolactam product, spiro[cyclohexane-1,1'-[1H]isoindole]-3',4(2'H)-dione, as a foamy white solid.

Mp 55-65°C. ¹H NMR DMSO d₆ 8.45 (br s, 1H), 7.88 (d, 7.4Hz, 1H), 7.61 (d, J=3.8Hz, 2H), 7.58-7.44 (m, 1H), 2.76 (dt, J₁=13.8Hz, J₂=6.0 Hz, 2H), 2.57-2.44 (m, 2H), 2.35-2.28 (m, 2H), 1.97-1.89 (m, 2H).

Examples for the preparation of intermediates III**EXAMPLE 9**4-(4-Cyano-3-fluoro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

2,4-Difluorobenzonitrile (5.00 g, 35.94 mmol), tert-butyl-1-piperazinecarboxylate (6.69g, 35.92 mmol) and potassium carbonate (10.0g, 72.4 mmol) were combined in dimethylsulfoxide (40 mL) and stirred at 150°C overnight. The reaction mixture was cooled to ambient temperature, poured into water (150 mL) and extracted into ethyl acetate (150 mL). The extract was washed twice with water and once with brine, dried over magnesium sulfate and concentrated. The residue was purified by flash chromatography (2"x5" silica gel). The column was flushed with 500 mL each 10% and 20% ethyl acetate/hexane and the product removed with an additional 500 mL of 20 % ethyl acetate/hexane. Concentration gave 4-(4-cyano-3-fluoro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester as a white solid (3.28g, 30%) which had mp 130.5-131.0°C.

¹H NMR CDCl₃ δ 7.42 (t, J=8.2Hz, 1H), 6.63 (dd, J₁=8.9 Hz, J₂=2.4 Hz, 1H), 6.55 (dd, J₁=12.67 Hz, J₂=2.3 HZ, 1H), 3.59 (t, J=5.3 Hz, 4H), 3.34 (t, J=5.3 Hz, 4H), 1.49 (s, 9H).

EXAMPLE 10**2-Fluoro-4-piperazin-1-yl-benzonitrile**

A solution of 4-(4-cyano-3-fluoro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (6.97g, 22.83 mmol) in methanol (250 mL) was saturated with HCl gas and stirred at ambient temperature overnight. The reaction was concentrated, saturated sodium bicarbonate (250 mL) was added and the slurry was stirred for 1 hour. The resulting solid was filtered off, rinsed well with water, air dried then evacuated overnight. As water was removed from the solid, it turned to a milky yellow solid which slowly solidified to give 2-fluoro-4-piperazin-1-yl-benzonitrile as a waxy solid (3.84g, 82%).

mp 67-68°C.

¹H NMR CDCl₃ δ 7.33 (dd, J₁=8.8 Hz, J₂= 7.8 Hz, 1H), 6.58 (dd, J₁=8.9 Hz, J₂=2.4 Hz, 1H), 6.49 (dd, J₁= 13.1 Hz, J₂=2.4 Hz, 1H), 3.27-3.23 (m, 4H), 2.97-2.93 (m, 4H), 1.70 (s, 1H).

¹³C NMR CDCl₃ δ 166.46, 163.09, 155.67, 155.53, 133.81, 133.78, 115.41, 109.77, 109.75, 100.63, 100.31, 88.15, 87.80, 47.98, 45.59.

Analysis calculated for C₁₁H₁₂FN₃: C, 64.37; H, 5.89; N, 20.47. Found: C, 64.33; H, 5.82; N, 20.35.

Preparation of compounds with general formula IV**EXAMPLE 11****1-(4-Fluoro-phenyl)-4-cyclohexanone**

A solution of 1-(1,4-dioxo-spiro[4.5]dec-8-yl)-4-(4-fluoro-phenyl)-piperazine (3.13 gm) (C₁₈H₂₅FN₂O₂) in 100 ml 3N hydrochloric acid and 100 ml dioxane was stirred at ambient temperature for 2 hours. The mixture is cooled to 0 °C, neutralized with 2N sodium hydroxide and extracted with 2 x 100 ml ethyl acetate. The ethyl acetate layer was washed with water and brine (each 2 x 40 ml), dried over sodium sulfate and concentrated to a solid. This material, which was recrystallized from ethyl ether (1.5 gm), has a melting point of 104-106°C.

Elemental analysis of a sample of this material (C₁₆H₂₁FN₂O): C 69.61 %, H 7.9 %, N 10.3 %.

Example for the preparation of intermediate VIII

EXAMPLE 12**2-Fluoro-4-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-benzonitrile)**

To a 100 ml 3-necked flask was added (2.01 g, 0.0107 mol) 2-bromobenzyl
5 alcohol and 23 ml dry THF. The reaction mixture was cooled to -60°C (dry ice/
acetone bath). 2.0 Equivalents of n-butyl lithium (8.60ml) were added in 0.5 ml
increments over approximately 30 minutes (min). The temperature was maintained
below -40°C during the addition. The dianion (lithium salt) began to precipitate after
15 min. The mixture was allowed to warm to -20°C by removing the dry ice acetone
10 bath. A thick white precipitate formed which is the dianion salt. After stirring approx.
1 1/2 hours, the flask was again cooled to -60°C. 1,4 Cyclohexanedione ethylene ketal
(1.68 g, 0.0107 mol) in 10 ml THF was added via an addition funnel. The temperature
was kept below -40°C. When the addition was complete, the flask was allowed to
slowly warm to room temperature and the reaction was stirred 18 hours at room
15 temperature.

To quench the reaction, excess aqueous ammonium chloride was added. The
THF was removed by rotary evaporation. 2ml Ethyl acetate was added. The organic
layer was washed with water and the water layer was back extracted. The organic
extractions were combined and dried with MgSO₄. The organics were concentrated
20 down, leaving a thick yellow oil. Hexane: ethyl acetate (1:1) was added and a
precipitate began to form. The precipitate was filtered off and the procedure with the
mother liquor. 2.23g repeated to yield a white solid, 8-(2-Hydroxymethyl-phenyl)-1,4-
dioxo-spiro[4.5]decan-8-ol, 80% yield.

Example for the preparation of compounds with general structure IX

25

EXAMPLE 13**1-(1,4-Dioxo-spiro[4.5]dec-8-yl)-4-(4-fluoro-phenyl)-piperazine**

A mixture of 11.5 gm of 1-(4-fluoro-phenyl)-piperazine 10.0 gm of 1,4-
cyclohexanedione mono-ethylene ketal (available from Aldrich) and 27.2 gm NaB(OAc)₃
in 250 ml dichloroethylene was kept for 18 hours at ambient temperature. The solvents
30 were removed and the residue partitioned between ethyl acetate (200 ml) and 2N NaOH
(200 ml). The ethyl acetate layer is washed with 2x 20 ml water and dried over Na₂SO₄.
The crude 1-(1,4-dioxo-spiro[4.5]dec-8-yl)-4-(4-fluoro-phenyl)-piperazine (20.1 gm of a
solid) obtained after removing the solvents had a melting point of 116-118°C. A

sample of this material ($C_{18}H_{25}FN_2O_2$) showed an elemental analysis of C 67.24 %, H 8.22%, N 8.98%.

Example for preparation of compounds with general structure X

EXAMPLE 14

5 **1,7,10-Trioxa-dispiro[2.2.4.2]dodecane**

12.00g (76.83mmol, 1.0 equiv.) of 1,4 Cyclohexanedione ethylene ketal was added to 120 ml methylene chloride along with 18.8 g (99.88 mmol, 1.3 equiv.) of trimethyl sulfonium methyl sulfate. 40 ml 50% sodium hydroxide (NaOH) was added last and the reaction was refluxed for 24 hours. The methylene chloride was removed, 10 200 ml ether was added and the ether layer was washed with water. The organic layer was dried with sodium sulfate and concentrated down, leaving a yellow oil, 1,7,10-trioxa-dispiro[2.2.4.2]dodecane. (12.13g, 93% yield). No further purification was necessary.

GC-MS FW=170.21

15 1 peak at 1.456 min.

1H NMR (250 MHz, $CDCl_3$) δ .4-1.8 (8 H, m), 2.6 (2H, s), 3.9 (4H, s).

^{13}C NMR (63 MHz, $CDCl_3$) δ 107.59, 63.98, 57.12, 53.31, 32.54, 30.12.

Example for the preparation of compounds with general structure XII

EXAMPLE 15

20 **8-(2-Bromo-phenoxy-methyl)-1,4-dioxo-spiro[4.5]decan-8-ol**

11.98g (70.38 mmol, 1.0 equiv.) of epoxide 1,7,10-Trioxa-dispiro[2.2.4.2]dodecane, was added to a 250 ml round-bottom flask containing 100 ml of toluene. 2-Bromo phenol (8.03 ml, 70.38 mmol, 1.0 equiv.) was then added via a syringe and the contents of the flask were stirred for 5 minutes. 5.69ml (1.0 equiv.) 25 Pyridine was then added and the reaction was refluxed 18 hours.

WORK-UP: Concentrate crude reaction mixture, add 200 ml ethyl acetate and wash with water, dry organic layer with sodium sulfate. Dark brown oil subjected to flash chrom. 20% ethyl acetate, Hex. (6.10g, yellow oil, 25% yield).

GC-MS FW=343.42

30 6.923 min.

1H NMR (250 MHz, $CDCl_3$) δ 1.6-1.8 (4H, m), 1.8-2.1 4H, m), 2.3 (1H, s), 3.85 (2H, s). 3.9-4.0 (4H, m), 6.8 (2H, m), 7.2 (1H, m), 7.5 (1H, m).

-37-

^{13}C NMR (75MHz, CDCl_3) δ 154.92, 133.21, 128.56, 122.33, 113.69, 112.48, 108.79, 76.74, 69.85, 64.32, 64.19, 31.74, 30.01.

Example for preparation of compounds with general structure XIII

EXAMPLE 16

5 **8-(2-Bromo-phenoxy)methyl)-1,4-dioxo-spiro[4.5]dec-7-ene**

8-(2-Bromo-phenoxy)methyl)-1,4-dioxo-spiro[4.5]decan-8-ol (2.6498g, 7.72mmol, 1.0 equiv.) was added to a dry 3-necked flask with 15ml CH_2Cl_2 and (4.03ml, 3.0 equiv.) of diisopropylethylamine. The reaction was then cooled to -12°C and 2.02g (1.5 equiv.) of methane sulfonic acid in 15ml CH_2Cl_2 was added dropwise. The reaction was
10 allowed to warm to room temperature. After 1 hour, 25ml water and 25 ml CH_2Cl_2 were added. The organic layer was dried with sodium sulfate and concentrated, leaving a yellow oil. Flash chromatography (10 % EtOAc, hexane) gave 0.7569g oil of an 8-(2-bromo-phenoxy)methyl)-1,4-dioxo-spiro[4.5]dec-7-ene, 30% yield.

GC-MS FW=325.20

15 1 peak at 6.4556 min.

^1H NMR (250 MHz, CDCl_3) δ 1.83 (2H, t), 2.40 (4H, m), 3.98 (4H, s), 4.47 (2H, s), 5.77 (1H, br singlet), 6.81-6.89 (2H, m), 7.19-7.25 (1H, m), 7.50-7.54 (1H, m).

^{13}C NMR (63 MHz, CDCl_3) δ 24.79, 30.76, 35.45, 64.38, 72.27, 107.84, 112.29, 113.58, 121.84, 122.34, 128.36, 132.86, 133.23, 155.04.

20 **Example for preparation of compounds with general structure XVII**

EXAMPLE 17

Spiro-[(cyclohexan-1,3'-isoindolin)-1'-one]-4-one

A solution of 2-bromobenzonitrile (2.00g, 10.99 mmol) in tetrahydrofuran (50 mL) was cooled to -78°C and *n*-butyllithium (2.5M, 4.6 mL, 11.5 mmol) was added slowly. The
25 resulting orange-brown solution was stirred for 10 min., then a solution of 1,4-cyclohexanedione mono-ethylene ketal (1.70 g, 10.88 mmol) in tetrahydrofuran (25 mL) was added dropwise over 5 minutes. The reaction was stirred an additional 15 min, quenched with water (25 mL) and immediately extracted into chloroform (100 mL). This extract was dried over magnesium sulfate and concentrated to give the crude
30 spiroimide as a waxy yellow solid (2.74g, 97%).

Mp $178-179^\circ\text{C}^{41}$

-38-

^1H NMR CDCl_3 δ 7.81 (d, $J=7.4$ Hz, 1H), 7.54 (dt, $J_1=7.3$ Hz, $J_2=1.1$ Hz, 1H), 7.45 (dt, $J_1=7.4$ Hz, $J_2=1.0$ Hz, 1H), 7.33 (d, $J=7.4$ Hz, 1H), 4.05-3.98 (m, 2H), 2.45-2.05 (m, 4H), 1.79 (br d, $J=10.0$ Hz, 4H).

Analysis calculated for $\text{C}_{15}\text{H}_{17}\text{NO}_3$; C, 69.46; H, 6.61; N, 5.40. Found: C, 69.33;
5 H, 6.62; N, 5.01.

Additional Examples for preparing compounds with general structure XVII

EXAMPLE 18

3'H-Spiro[cyclohexane-1,1'-benzofuran]-4-one diethylacetal

0.7112g (2.19mmol, 1.0 equiv.) of 8-(2-Bromo-phenoxy-methyl)-1,4-dioxaspiro[4.5]dec-7-ene, was added to toluene, 40ml, along with (2.0 equiv., 1.18ml, 4.38mmol) of tributyltin hydride. AIBN (13mol %) was then added and the reaction was refluxed for 3 hours. Ethyl acetate (EtOAc) (15ml) and 3.0 ml aqueous potassium fluoride were added. The reaction was stirred overnight and a white precipitate was filtered off. The EtOAc layer was washed with water and the organic layer was dried
15 with sodium sulfate. Flash chromatography (10% EtOAc, hexane) yielded a white solid.

GC-MS FW= 246.31

1 peak at 4.950 min.

^1H NMR (250 MHz, CDCl_3) δ 1.56-2.15 (8H, m), 3.9 (4H, s), 4.4 (2H, s), 6.8-6.9 (2H, m), 7.1-7.2 (2H, m).

20 ^{13}C NMR (63 MHz, CDCl_3) δ 159.32, 134.98, 128.28, 122.96, 120.50, 109.71, 107.90, 80.50, 64.34, 45.23, 34.02, 32.04.

Examples for the preparation of compounds with general structure III wherein PG = tertiary butoxy carbonyl

EXAMPLE 19

25 trans-4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine-1-carboxylic acid tert-butyl ester maleate

tert-Butyl 1-piperazinecarboxylate (0.86g, 4.62 mmol), 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4-one (0.93g, 4.60 mmol) and sodium triacetoxyborohydride (1.96g, 9.25 mmol) were stirred in 1,2-dichloroethane (50 mL) overnight at ambient
30 temperature. The reaction was concentrated and stirred 1 hour with 25 mL each 1N sodium hydroxide and ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and concentrated to a thick colorless oil (1.74g). The crude product was loaded onto a silica gel column (1.5" x 4") and flushed with 20% ethyl

-39-

acetate/hexane (250 mL). An additional 250 mL 20% ethyl acetate/hexane and 250 mL 30% ethyl acetate/hexane gave, after concentration, trans-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine-1-carboxylic acid tert-butyl ester as a white solid (0.56 g, 33%). A portion of this was converted to the maleate salt in diethyl ether with 1 equiv. of maleic acid.

Mp 168-169°C.

Analysis calculated for $C_{22}H_{32}N_2O_3 \cdot C_4H_4O_4$: C, 63.92; H, 7.43; N, 5.73. Found: C, 63.60; H, 7.03; N, 5.84.

Preparation of compounds with general structure Intermediates XX

10

EXAMPLE 20

trans-1-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine dihydrochloride

HCl gas was bubbled through a solution of trans-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine-1-carboxylic acid tert-butyl ester (0.52g, 1.40 mmol) in ethyl ether (100mL) for 3 min. Methanol (25 mL) was added to dissolve precipitated solids and the reaction was stirred at ambient temperature for 4 days. Filtered off the precipitate and air dried to yield 0.45g (94%) of trans 1-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine dihydrochloride as a white solid.

Mp >260°C.

Analysis calculated for $C_{17}H_{24}N_2O \cdot 2HCl \cdot 0.5H_2O$: C, 57.63; H, 7.68; N, 7.91. Found: C, 58.01; H, 7.73; N, 7.95.

Using methods Scheme 1 and Scheme 3, the following compounds with general formula I were prepared.

EXAMPLE 21

trans-4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-spiro[cyclohexane-1-1'-isobenzofuran]-3'-one maleate

mp=194-195°C.

Analysis calculated for $C_{23}H_{25}FN_2O_2 \cdot C_4H_4O_4$: C, 65.31; H, 5.89; N, 5.64. Found: C, 65.09; H, 6.00; N, 5.55.

EXAMPLE 22

trans, 1-(4-Fluoro-phenyl)-4-3'H-spiro[cyclohex-1-1'-isobenzofuran]-4-yl-
piperazine mesylate

mp >260°C.

5 Analysis calculated for $C_{23}H_{27}FN_2O \cdot CH_4O_3S$: C, 62.32; H, 6.75; N, 6.06. Found:
C, 62.05; H, 7.01; N, 5.94.

EXAMPLE 23

trans, 1-(4-Fluoro-phenyl)-4-(5',6',7'-trifluoro-3'H-spiro[cyclohex-1,1'-
isobenzofuran]-4-yl)-piperazine dihydrochloride

10 mp=256-258°C.

Analysis calculated for $C_{23}H_{24}F_4N_2O \cdot 2HCl \cdot 0.75H_2O$: C, 54.50; H, 5.46; N, 5.52.
Found: C, 54.27; H, 5.43; N, 5.44.

EXAMPLE 24

trans, 1-(5'-Chloro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-
15 phenyl)-piperazine dihydrochloride

mp >260°C.

Analysis calculated for $C_{23}H_{26}ClFN_2O \cdot 2HCl \cdot 0.25H_2O$: C, 57.75; H, 6.00; N,
5.86. Found: C, 57.71; H, 6.03; N, 5.81.

EXAMPLE 25

20 trans, 1-(4-Fluoro-phenyl)-4-(4'-trifluoromethyl-3'H-spiro[cyclohex-1,1'-
isobenzofuran]-4-yl)-piperazine dihydrochloride

mp >260°C.

Analysis calculated for $C_{24}H_{26}F_4N_2O \cdot 2HCl$: C, 56.81; H, 5.56; N, 5.52. Found:
C, 56.64; H, 5.49; N, 5.66.

25

EXAMPLE 26

trans, 6'-Fluoro-4-[4-(4-fluoro-phenyl)-piperazin-1-yl]- spiro[cyclohexane-1,1'-
isobenzofuran]-3'-one

$C_{23}H_{24}F_2N_2O_2$, FW=398.45, 434.92 HCl.

GC-MS 8.8 Min., M+ 398.

30

mp >250°C.

1H NMR ($CDCl_3$, 250 MHz) δ 1.60-1.65 (m, 2H), 2.0-2.1 (m, 4H), 2.3-2.4 (m, 2H),
2.5 (m, 1H), 2.7 (m, 4H), 3.2 (m, 4H), 6.8-7.0 (m, 4H), 7.1-7.2 (m, 2H), 7.9 (m, 1H).

-41-

^{13}C NMR (CDCl_3 , 63 MHz) δ 24.50, 31.46, 50.05, 50.45, 57.31, 86.5, 108.59, 108.97, 115.30, 115.65, 116.96, 117.34, 177.55, 117.67, 128.13, 128.29, 159.01.

EXAMPLE 27

5 trans, 1-(2-chloro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-
piperazine dihydrochloride

mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{23}\text{H}_{27}\text{ClN}_2\text{O} \bullet 2\text{HCl} \bullet \text{H}_2\text{O}$: C, 58.30; H, 6.59; N, 5.91.
Found: C, 58.16; H, 6.53; N, 5.82.

10 **EXAMPLE 28**

trans, 1-(2-Methoxy-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-
piperazine dihydrochloride

mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{24}\text{H}_{30}\text{N}_2\text{O}_2 \bullet 2\text{HCl}$: C, 63.85; H, 7.14; N, 6.21. Found: C,
15 64.10; H, 6.84; N, 5.73.

EXAMPLE 29

trans, 1-(4'-Bromo-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-
phenyl)-piperazine dihydrochloride

mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{23}\text{H}_{26}\text{BrFN}_2\text{O} \bullet 2\text{HCl} \bullet 0.5\text{H}_2\text{O}$: C, 52.39; H, 5.54; N, 5.31.
Found: C, 52.55; H, 5.57; N, 5.51.

EXAMPLE 30

trans, 1-(4-Fluoro-phenyl)-4-(5'-fluoro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-
yl)-piperazine dihydrochloride

25 mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{23}\text{H}_{26}\text{F}_2\text{N}_2\text{O} \bullet 2\text{HCl} \bullet \text{H}_2\text{O}$: C, 58.11; H, 6.36; N, 5.89.
Found: C, 58.44; H, 6.64; N, 5.66.

EXAMPLE 31

trans, 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4'-carbonitrile dihydrochloride

mp >260°C.

5 Analysis calculated for $C_{24}H_{28}FN_3O \bullet 2HCl$: C, 62.07; H, 6.08; N, 9.05. Found: C, 62.00; H, 6.23; N, 8.52.

EXAMPLE 32

trans, 4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4'-carboxylic acid amide dihydrochloride

10 mp >260°C.

Analysis calculated for $C_{24}H_{28}FN_3O_2 \bullet 2HCl \bullet 1.5H_2O$: C, 56.58; H, 6.53; N, 8.24. Found: C, 56.15; H, 6.52; N, 7.89.

EXAMPLE 33

trans, 2-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)- benzonitrile

15 $C_{24}H_{27}N_3$, FW=373.50 (FREEBASE), 409.95 HCl.

GC-MS 9.3 Min., M^+ 373.

mp >250°C (HCl).

^{13}C NMR ($CDCl_3$, 63MHz) δ 24.70, 33.49, 49.82, 51.87, 59.50, 70.43, 86.73, 105.70, 118.46, 121.10, 121.41, 121.49, 126.96, 127.34, 133.74, 134.35, 139.25, 146.17, 155.68.

EXAMPLE 34

trans, 1-(2-Fluoro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine

$C_{23}H_{27}FN_2O$, FW=366.48, 402.93 HCl.

25 GC-MS 7.67 Min., M^+ 366.

mp >250°C.

^{13}C NMR ($CDCl_3$, 75 MHz) δ 24.81, 33.47, 50.03, 50.99, 51.04, 59.54, 70.48, 86.86, 115.95, 116.23, 118.81, 118.85, 121.12, 121.46, 122.24, 122.34, 124.41, 124.45, 127.00, 127.36, 139.29, 140.21, 140.31, 146.30, 154.16, 157.42.

EXAMPLE 35

trans, 1-(2,4-Dimethyl-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-
piperazine

$C_{25}H_{32}N_2O$, FW=376.55, HCl 413.00.

5 GC-MS 8.37 Min., M^+ 376.

mp > 250°C.

EXAMPLE 36

trans, 5-Fluoro-2-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-
benzonitrile

10 $C_{24}H_{26}FN_3O$, FW=391.49, 427.94 HCl.

GC-MS 8.84 Min., M^+ 391.

mp > 250°C.

^{13}C NMR ($CDCl_3$, 75 MHz) δ 24.75, 33.51, 49.87, 52.41, 59.50, 70.48, 77.32,
86.76, 107.17, 107.30, 117.12, 117.16, 120.24, 120.35, 120.55, 120.92, 121.16, 121.20,
15 121.42, 127.01, 127.23, 127.39, 127.49, 139.31, 146.23, 152.57, 152.61, 155.26, 158.48.

EXAMPLE 37

trans, 2-Fluoro-4-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-
benzonitrile

mp HCl >250°C, mesylate 263°C (decomposition).

20 1H NMR ($CDCl_3$, 400MHz) δ 1.6 (m, 2H), 1.9 (m, 4H), 2.0 (m, 2H), 2.4 (s, 1H),
2.69 (m, 4H), 3.37 (m, 4H), 5.0 (s, 2H), 6.63 (m, 2H), 7.2 (m, 4H), 7.4 (m, 1H).

^{13}C NMR ($CDCl_3$, 100 MHz) δ 24.7, 33.0, 47.3, 49.4, 58.9, 70.5, 86.7, 100.4,
100.6, 109.7, 115.4, 121.1, 121.2, 127.1, 127.4, 133.9, 139.2, 146.2, 155.2, 155.3, 166.1.

Analysis calculated for $C_{24}H_{26}FN_3O$ HCl: C, 67.36; H, 6.36; N, 9.82. Found: C,
25 67.04; H, 6.48; N, 9.94.

EXAMPLE 38

trans, 1-(2-Ethoxy-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-
piperazine

$C_{25}H_{32}N_2O_2$, FW=392.54, 428.99 HCl.

30 GC-MS 8.59 Min., M^+ 392.

mp > 250°C.

-44-

^{13}C NMR (CDCl_3 , 75 MHz) δ 14.98, 24.90, 33.61, 50.24, 51.00, 59.83, 63.57, 70.48, 86.91, 112.51, 118.07, 121.02, 121.10, 121.56, 122.61, 124.11, 127.23, 127.34, 139.30, 141.53, 146.33, 151.62.

EXAMPLE 39

5 trans, 1-(4-Fluoro-phenyl)-4-(4'-fluoro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazine dihydrochloride

mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{23}\text{H}_{26}\text{F}_2\text{N}_2\text{O} \bullet 2\text{HCl} \bullet 3\text{H}_2\text{O}$: C, 54.01; H, 6.70; N, 5.48.
Found: C, 54.05; H, 6.70; N, 5.48.

10 **EXAMPLE 40**

trans, 4-[4-(2-Cyano-4-fluoro-phenyl)-piperazin-1-yl]-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4'-carbonitrile hydrochloride

mp $>260^\circ\text{C}$.

Analysis calculated for $\text{C}_{25}\text{H}_{25}\text{FN}_4\text{O} \bullet \text{HCl}$: C, 66.29; H, 5.79; N, 12.37. Found: C, 65.85; H, 5.96; N, 12.26.

EXAMPLE 41

trans, 2-[4-(4'-Cyano-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazin-1-yl]-5-fluoro-benzamide dihydrochloride

mp $>260^\circ\text{C}$.

20 ^{13}C NMR DMSO d_6 δ 11.03 (br s, 1H), 8.30-8.27 (m, 2H), 7.80 (d, $J=7.3\text{Hz}$, 1H), 7.69 (br s, 1H), 7.52 (t, $J=7.7\text{Hz}$, 1H), 7.46 (dd, $J_1=9.4\text{Hz}$, $J_2=3.1\text{Hz}$, 1H), 7.38-7.31 (m, 1H), 7.30-7.24 (m, 1H), 5.17 (s, 2H), 3.78 (br d, $J=10.2\text{Hz}$, 2H), 3.50-3.35 (m, 3H), 3.30-3.15 (m, 4H), 2.40-2.27 (m, 2H), 2.25-2.14 (m, 4H), 1.73-1.67 (m, 2H).

EXAMPLE 42

25 trans, 4-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazin-1-yl)- benzonitrile

$\text{C}_{24}\text{H}_{27}\text{N}_3\text{O}$, FW=373.50, 409.96 HCl.

GC-MS 10.51 Min., M^+ 373.

mp $>250^\circ\text{C}$.

30 ^{13}C NMR (CDCl_3 , 63MHz) δ 24.71, 31.82, 33.06, 35.27, 47.44, 49.54, 58.99, 70.46, 70.69, 86.70, 100.0, 113.97, 120.11, 121.11, 121.26, 127.01, 127.18, 127.39, 133.41, 139.14, 146.14, 153.38.

EXAMPLE 43

trans, 1-(4'-Chloro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-phenyl)-piperazine dihydrochloride

mp >260°C.

5 Analysis calculated for $C_{23}H_{26}ClFN_2O \bullet 2HCl$: C, 58.30; H, 5.96; N, 5.91. Found: C, 58.52; H, 5.95; N, 5.61.

EXAMPLE 44

trans, 4-[4-(4-Cyano-phenyl)-piperazin-1-yl]-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-4'-carbonitrile hydrochloride

10 mp >260°C.

EXAMPLE 45

trans, 1-(4-Methoxy-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine dihydrochloride

mp >260°C.

15 Analysis calculated for $C_{24}H_{30}N_2O_2 \bullet 2HCl$: C, 63.85; H, 7.14; N, 6.21. Found: C, 63.74; H, 7.07; N, 5.90.

EXAMPLE 46

trans, 1-(4-chloro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine dihydrochloride

20 mp >260°C.

Analysis calculated for $C_{23}H_{27}ClN_2O \bullet 2HCl$: C, 60.60; H, 6.41; N, 6.15. Found: C, 60.22; H, 6.24; N, 6.03.

EXAMPLE 47

25 trans, 1-(4-Nitro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine hydrochloride

mp >260°C.

Analysis calculated for $C_{23}H_{27}N_3O_3 \bullet HCl \bullet 0.25H_2O$: C, 63.59; H, 6.61; N, 9.67. Found: C, 63.52; H, 6.75; N, 9.48.

-46-

EXAMPLE 48

trans, 2-Fluoro-4-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-benzamide

$C_{24}H_{28}FN_3O_2$, FW=409.51, 445.97 HCl.

5 MS M+1 = 410.

mp >250°C HCl.

^{13}C NMR ($CDCl_3$, 75 MHz) δ 24.70, 33.07, 47.59, 49.49, 70.45, 86.72, 100.01, 100.48, 110.00, 121.10, 121.26, 127.0, 127.37, 133.06, 133.12, 139.14, 146.13, 155.25, 164.80, 165.27.

10

EXAMPLE 49

trans, 1-(3-Chloro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine

$C_{23}H_{27}ClN_2O$, FW=382.94, 419.40 HCl.

GC-MS 9.16 Min., M^+ 382.

15 mp >250°C HCl.

^{13}C NMR ($DMSO-d_6$, 75 MHz) δ 22.26, 33.24, 44.59, 48.72, 62.06, 69.89, 85.04, 114.09, 115.20, 119.17, 121.20, 122.48, 127.04, 127.56, 130.68, 134.00, 139.06, 145.04, 150.91.

EXAMPLE 50

20 trans, 1-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-4-m-tolyl- piperazine

$C_{24}H_{30}N_2O$, FW=362.52, 398.98 HCl.

GC-MS 8.50 Min., M^+ 362.

mp >250°C HCl.

25 ^{13}C NMR ($CDCl_3$, 62 MHz) δ 21.89, 24.87, 33.30, 49.62, 50.08, 59.30, 70.51, 77.43, 86.86, 113.12, 116.79, 120.52, 121.13, 121.44, 127.07, 127.38, 128.97, 138.67, 139.24, 146.35, 151.51.

EXAMPLE 51

trans, 2-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)- benzamide

$C_{24}H_{29}N_3O_2$, FW=391.52, 427.98 HCl.

30 ^{13}C NMR ($CDCl_3$, 63 MHz) δ 24.71, 33.14, 50.58, 53.71, 59.30, 70.46, 120.19, 121.09, 121.32, 124.59, 127.00, 127.38, 131.72, 132.46, 139.15, 168.60.

EXAMPLE 52

trans, 4-(4-3'H-Spiro[cyclohex-1-1'-isobenzofuran]-4-yl-piperazin-1-yl)-phenylamine dihydrochloride

mp >260°C.

5

EXAMPLE 53

trans, N-[4-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-phenyl]-acetamide dihydrochloride

mp >260°C.

Analysis calculated for $C_{25}H_{23}N_3O_2 \bullet 2HCl \bullet 0.5H_2O$: C, 61.60; H, 7.03; N, 8.61.

10 Found: C, 61.80; H, 7.03; N, 8.41.

EXAMPLE 54

trans, 6-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-nictinonitrile dihydrochloride

mp >260°C.

15 Analysis calculated for $C_{23}H_{26}N_4O \bullet 2HCl \bullet 1.5H_2O$: C, 58.23; H, 6.59; N, 11.81.

Found: C, 58.22; H, 6.54; N, 11.56.

EXAMPLE 55

cis, 1-(3,4-Dichloro-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine

20 $C_{23}H_{26}Cl_2N_2O$, FW=417.38, 453.84 HCl.

GC-MS 10.44 Min., (M-1) 416.

mp >250°C HCl.

1H NMR (DMSO- d_6 , 400MHz, HCl) δ 1.6 (m, 2H), 2.1 (m, 5H), 3.0-3.1 (m, 2H), 3.4 (m, 4H), 3.6-3.9 (m, 4H), 4.9 (s, 2H), 6.9-7.0 (m, 1H), 7.2-7.25 (m, 4H), 7.4 (m, 1H),

25 7.8 (m, 1H).

EXAMPLE 56

trans, 2-Fluoro-4-[4--(5'-fluoro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazin-1-yl]-benzonitrile hydrochloride

mp >260°C.

30 Analysis calculated for $C_{24}H_{25}F_2N_3O \bullet HCl$: C, 64.64; H, 5.88; N, 9.42. Found:

C, 64.50; H, 6.07; N, 9.49.

-48-

EXAMPLE 57

trans, 1-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-4-(3-trifluoromethyl-phenyl)-piperazine

$C_{24}H_{27}F_3N_2O$, FW=416.49, 452.95 HCl.

5 GC-MS 7.83 Min., M^+ 416.

^{13}C NMR ($CDCl_3$, 100 MHz) δ 24.80, 33.18, 49.03, 49.81, 59.18, 70.51, 86.81, 111.95, 111.99, 115.67, 118.60, 121.12, 121.38, 127.06, 127.41, 129.51, 131.54, 139.20, 146.24, 151.46.

EXAMPLE 58

10 trans, 4-Fluoro-2-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl- piperazin-1-yl)-benzonitrile

$C_{24}H_{26}FN_3O$, FW=391.49, 427.94 HCl.

GC-MS 9.02 Min., M^+ 391.

15 1H NMR ($DMSO-d_6$, 250 MHz, HCl) δ 1.6-1.7 (m, 2H), 2.1-2.2 (m, 7H), 3.1-3.9 (m, 8H), 5.0 (s, 1H), 7.1 (m, 1H), 7.2-7.3 (m, 6H), 7.9 (m, 2H).

EXAMPLE 59

trans, 1-3'H-Spiro[cyclohex-1-1'-isobenzofuran]-4-yl-4-(4-trifluoromethyl-phenyl)-piperazine hydrochloride

mp $>260^\circ C$.

20 Analysis calculated for $C_{24}H_{27}F_3N_2O \bullet HCl \bullet 0.25H_2O$: C, 63.02; H, 6.28; N, 6.12.
Found: C, 62.90; H, 6.28; N, 6.01.

EXAMPLE 60

trans, 1-(4-Methanesulfonyl-phenyl)-4-3'-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine hydrochloride

25 mp $>260^\circ C$.

Analysis calculated for $C_{24}H_{30}N_2O_3S \bullet HCl$: C, 62.25; H, 6.75; N, 6.05. Found: C, 61.99; H, 6.70; N, 5.91.

EXAMPLE 61

trans, 4-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-benzamide

$C_{24}H_{29}N_3O_2$, FW=391.52, 427.98 HCl MS (M+1) 392

H NMR (DMSO d_6 , 75MHz) δ 22.16, 33.14, 44.05, 48.63, 61.99, 69.82, 84.98,
5 114.08, 121.11, 122.42, 124.63, 126.97, 127.49, 128.82, 128.92, 138.97, 144.99, 151.43,
167.46.

EXAMPLE 62

trans, 1-Phenyl-4-3'H-spiro[cyclohex-1-1'-isobenzofuran]-4-yl-piperazine
dihydrochloride

10 mp >260°C.

Analysis calculated for $C_{23}H_{28}N_2O \cdot 2HCl$: C, 65.55; H, 7.18; N, 6.65. Found: C,
65.49; H, 7.47; N, 6.58.

EXAMPLE 63

trans, 2-Fluoro-4-[4-(6'-fluoro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-
15 piperazin-1-yl]-benzonitrile mesylate

mp =149-155° C.

Analysis calculated for $C_{24}H_{25}F_2N_3O \cdot CH_4O_3S \cdot 1.5H_2O$: C, 56.38; H, 6.06; N,
7.89. Found: C, 56.91; H, 5.83; N, 7.50.

EXAMPLE 64

20 trans, 4-[4-(5'-Chloro-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-
yl]-2-fluoro-benzamide dihydrochloride

mp >260° C.

1H NMR DMSO d_6 11.07 (br s, 1H), 7.66 (t, J=8.8Hz, 1H), 7.43-7.26 (m, 5H),
6.91-6.86 (m, 2H), 4.98 (s, 2H), 4.03 (br d, J=12.8Hz, 2H), 3.57-3.15 (m, 7H), 2.20-2.10
25 (m, 2H), 1.95-1.80 (m, 6H).

EXAMPLE 65

trans, 2-fluoro-4-[4-(5-fluorospiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl)-1-
piperazinyl]-, benzonitrile, hydrochloride,

$C_{24}H_{25}F_2N_3O$, FW=409.48, 445.93 HCl.

30 GC-MS 11.06 Min., M^+ 409.

MP >250°C.

-50-

EXAMPLE 66

trans, 1-(4'-Bromo-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-m-tolyl-
piperazine dihydrochloride

mp >260° C.

5 Analysis calculated for C₂₅H₂₉BrN₂O•2HCl: C, 56.05; H, 6.08; N, 5.45. Found:
C, 55.96; H, 5.95; N, 5.31.

Using the methods described in scheme 1 and 5 the title compounds of
Examples 67-69 have been prepared.

EXAMPLE 67

10 trans, 4-[4-(4-fluorophenyl)-1-piperazinyl]-spiro[cyclohexane-1,1'-[1H]isoindol]-
3'(2'H)-one dihydrochloride

mp=238.5-242°C.

Analysis calculated for C₂₃H₂₆•FN₃O•2HCl•2.5H₂O: C, 55.54; H, 6.28; N, 8.44.
Found: C, 55.49; H, 6.15; N, 8.24.

EXAMPLE 68

15 trans, 1-(3',3'-Dimethyl-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-(4-fluoro-
phenyl)-piperazine dihydrochloride

mp >260°C.

Analysis calculated for C₂₅H₃₁FN₂O•2HCl•0.25H₂O: C, 63.62; H, 7.15; N, 5.94.
20 Found: C, 63.50; H, 6.92; N, 5.59.

EXAMPLE 69

trans, 1-[4-fluorophenyl]-4-spiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl)- piperazine,
hydrochloride

MP >250°C (HCl).

25 ¹H NMR (250 MHz, CDCl₃) δ 1.5-1.8 (2H, br. m), 1.6-2.0 (6H, br. m), 2.45 (1H,
m), 2.7 (4H,m), 3.1 (4H, m), 6.8-7.4 (8H, aromatic).

¹³C NMR (63 MHz, CDCl₃) δ 24.93, 34.17, 45.11, 49.55, 50.53, 61.11, 83.34,
109.91, 115.29, 115.64, 117.63, 117.75, 120.16, 124.60, 128.19, 135.06, 148.01, 159.87.

EXAMPLE 70

trans, 2-fluoro-4-[4-spiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl]-1-piperaziny]-benzonitrile hydrochloride

$C_{24}H_{26}FN_3O$ (freebase), FW=391.49, 427.95 (HCl).

5 GC-MS 11.22 Min., M^+ 391.

MP > 250°C.

1H NMR ($CDCl_3$, 250 MHz) δ 1.5-1.6 (m, 2H), 1.9-2.1 (m, 6H), 3.1-3.2 (m, 2H), 3.2-3.3 (m, 3H), 3.8 (m, 2H), 4.1-4.2 (m, 3H), 6.9-7.0 (m, 2H), 7.0 (m, 1H), 7.2-7.3 (m, 2H), 7.7 (m, 2H).

EXAMPLE 71

10 trans, 4-[4-(5,6-difluorospiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl)-1-piperaziny]-2-fluoro-benzonitrile hydrochloride

$C_{24}H_{24}F_3N_3O$, FW=427.47, 463.93 HCl.

GC-MS 11.38 Min., M^+ 427.

15 ^{13}C NMR ($DMSO-d_6$, 75 MHz, HCl) δ 22.11, 32.76, 43.49, 44.05, 47.94, 62.48, 83.26, 87.43, 87.64, 99.15, 99.44, 100.99, 101.31, 110.73, 114.00, 114.28, 115.14, 129.94, 134.25, 154.12, 154.27, 162.57, 165.89 (some fluoride splitting not seen in this ^{13}C NMR).

EXAMPLE 72

20 trans, 4-(4-spiro[benzofuran-3(2H),1'-cyclohexan]-4'-yl)-1-piperaziny]-benzonitrile hydrochloride

$C_{24}H_{27}N_3O$, FW=373.50, 409.96 HCl.

GC-MS 11.03 Min., M^+ 373.

25 ^{13}C NMR ($DMSO-d_6$, 75 MHz) δ 22.38, 33.62, 43.54, 43.96, 48.09, 63.23, 82.5, 100.0, 109.84, 114.83, 120.17, 128.44, 133.53, 151.0, 159.0.

EXAMPLE 73

trans-4-Fluoro-2(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine-1-yl)benzonitrile hydrochloride

30 mp = > 250° C.

FW= 391.49 (freebase), GC-MS, t_R = 8.89 min., M^+ = 391.

-52-

^1H NMR (CDCl_3 , 300 MHz) δ 1.5-1.6 (m, 2H), 1.8-2.1 (m, 6H), 2.45 (s, 1H), 2.7 (br. s., 4H), 3.3 (br. s., 4H), 5.1 (s, 2H), 6.6-6.7 (m, 2H), 7.1 -7.3 (m, 5H), 7.55-7.60 (m, 1H).

^{13}C NMR (CDCl_3 , 75MHz) δ 24.70, 33.36, 49.73, 51.53, 59.40, 70.75, 77.42, 86.71, 101.03, 101.07, 105.85, 106.16, 108.59, 108.90, 117.99, 121.16, 121.40, 126.67, 127.05, 127.40, 136.34, 136.48, 139.27, 146.22, 157.90, 158.03, 164.31, 167.69.

EXAMPLE 74

trans-2-Fluoro-4-[4-(5-fluorospiro[benzofuran-3(2H), 1'-cyclohexan]-4'-yl)-1-piperazinyl]-benzonitrile hydrochloride

10 mp = > 250°C.

FW = 409.48 (freebase), GC-MS, t_R = 11.058min., M^+ = 409.

EXAMPLE 75

trans-1-(4'-Bromo-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-4-m-tolyl-piperazine dihydrochloride

15 mp > 260°C.

Analysis calculated for $\text{C}_{24}\text{H}_{29}\text{BrN}_2\text{O} \cdot 2 \text{HCl}$: C, 56.05; H, 6.08; N, 5.45. Found: C, 55.96; H, 5.95; N, 5.31.

EXAMPLE 76

20 trans-2-[4-(3',3'-Dimethyl-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazin-1-yl]-5-fluoro-pyrimidine mesylate

FW = 396.51 (freebase), GC-MS, t_R = 7.457 min., M^+ = 396.

^1H NMR (CDCl_3 , 300 MHz) δ 1.5 (s, 6H), 1.6-1.7 (m, 2H), 1.8-2.1 (m, 6H), 2.4-2.5 (m, 1H), 2.6 (m, 4H), 3.8 (m, 4H), 7.1-7.2 (m, 1H), 7.25-7.4 (m, 3H), 8.2 (s, 2H).

25 ^{13}C NMR (CDCl_3 , 75 MHz) δ 24.75, 31.06, 36.43, 44.82, 49.67, 60.11, 83.46, 85.12, 120.93, 121.71, 127.09, 127.66, 144.95, 145.23, 145.35, 147.07, 149.92, 153.21, 158.97.

EXAMPLE 77

cis-4-[4-(4-Fluorophenyl)-1-piperazinyl]-2', 3'-dihydro-spiro[cyclohexane-1,1'-[1H]inden]-3'-ol maleate

30 mp 200-201.5°C.

-53-

Analysis calculated for $C_{24}H_{29}FN_2O \cdot 0.75 C_4H_4O_4 \cdot 0.75 H_2O$: C, 67.41; H, 7.02; N, 5.82. Found: C, 67.24; H, 6.71; N, 5.66.

EXAMPLE 78

5 cis-4-[4-(4-Fluorophenyl)-1-piperazinyl]-spiro[cyclohexane-1,1'-[1H]inden]-3'(2'H)-one, O-methyloxime, dihydrochloride

mp >260°C.

Analysis calculated for $C_{25}H_{30}FN_3O \cdot 2 HCl \cdot 0.50 H_2O$: C, 61.35; H, 6.80; N, 8.59. Found: C, 61.51; H, 6.96; N, 8.57.

EXAMPLE 79

10 cis-4-[4-(4-Fluorophenyl)-1-piperazinyl]-spiro[cyclohexane-1,1'-[1H]inden]-3'(2'H)-one dihydrochloride

mp >260°C.

Analysis calculated for $C_{24}H_{27}FN_2O \cdot 2 HCl \cdot 0.50 H_2O$: C, 62.61; H, 6.57; N, 6.08. Found: C, 62.66; H, 6.38; N, 6.17.

15 **EXAMPLE 80**

1-(1,4-Dioxa-spiro[4.5]dec-8-yl)-4-(4-fluoro-phenyl)-piperazine

mp 116-118°C.

Analysis calculated for $C_{18}H_{25}FN_2O_2$: C, 67.48; H, 7.86; N, 8.74. Found: C, 67.24; H, 8.22; N, 8.98.

20 **EXAMPLE 81**

cis-1-(4-Fluorophenyl)-4-spiro[cyclohexane-1,1'-[1H]inden]-4-yl-piperazine maleate

mp 231-233.5°C.

25 Analysis calculated for $C_{24}H_{27}FN_2 \cdot C_4H_4O_4 \cdot 0.25 H_2O$: C, 69.62; H, 6.57; N, 5.80. Found: C, 69.77; H, 6.43; N, 5.72.

-54-

EXAMPLE 82

cis-1-(2',3'-Dihydrospiro[cyclohexane-1,1'-[1H]inden]-4-yl)-4-(4-fluorophenyl)-piperazine dihydrochloride

mp >260°C.

5 Analysis calculated for $C_{24}H_{29}FN_2 \cdot 2 HCl$: C, 65.90; H, 7.14; N, 6.40. Found: C, 65.63; H, 7.04; N, 6.29.

EXAMPLE 83

cis-4-[4-(2',3'-Dihydro-3'-hydroxyspiro[cyclohexane-1,1'-[1H]inden]-4-yl)-1-piperazinyl]-2-fluoro-benzonitrile maleate

10 mp 204-205°C.

Analysis calculated for $C_{25}H_{28}FN_3O \cdot C_4H_4O_4 \cdot 0.25 H_2O$: C, 66.21; H, 6.23; N, 7.99. Found: C, 66.27; H, 6.24; N, 7.88.

EXAMPLE 84

cis-4-[Spiro[cyclohexane-1,1'-[1H]inden]-3'(2'H)-one]-1-piperazinyl]-2-fluoro-benzonitrile hydrochloride

15

mp >260°C.

Analysis calculated for $C_{25}H_{26}FN_3O \cdot HCl \cdot 0.25 H_2O$: C, 67.56; H, 6.24; N, 9.45. Found: C, 67.52; H, 6.44; N, 9.38.

EXAMPLE 85

trans-1-[4-(1,1-Dioxidospiro[benzo[b]thiophene-3(2H),1'-cyclohex]-4'-yl)]-4-(4-fluorophenyl)-piperazine maleate

20

mp 214.5-215.5°C.

Analysis calculated for $C_{23}H_{27}FN_2O_2S \cdot C_4H_4O_4$: C, 61.12; H, 5.89; N, 5.28. Found: C, 60.88; H, 5.88; N, 4.69.

25

EXAMPLE 86

trans-4-[4-(1,1-Dioxidospiro[benzo[b]thiophene-3(2H),1'-cyclohex]-4'-yl)-1-piperaziny]-2-fluoro-benzonitrile maleate

mp 140-143° C.

- 5 Analysis calculated for $C_{24}H_{26}FN_3O_2S \cdot 0.25 C_4H_4O_4 \cdot 0.25 H_2O$: C, 60.04; H, 5.49; N, 7.50. Found: C, 59.73; H, 5.94; N, 5.79.

EXAMPLE 87

10 cis-4-[4-(2',3'-Dihydro-3'-hydroxyspiro[cyclohexane-1,1'-[1H]inden]-4-yl)-1-piperaziny]-2-fluoro-benzonitrile maleate (- enantiomer)

mp 206-207° C.

Analysis calculated for $C_{25}H_{28}FN_3O \cdot C_4H_4O_4$: C, 66.78; H, 6.18; N, 8.06. Found: C, 66.48; H, 6.03; N, 7.98. $[\alpha]_D = -10.22$, $c=0.450$ (MeOH)

EXAMPLE 88

15 cis-4-[4-(2',3'-Dihydro-3'-hydroxyspiro[cyclohexane-1,1'-[1H]inden]-4-yl)-1-piperaziny]-2-fluoro-benzonitrile maleate (+ enantiomer)

mp 199-199.5° C.

Analysis calculated for $C_{25}H_{28}FN_3O \cdot C_4H_4O_4 \cdot 0.50 H_2O$: C, 65.48; H, 6.26; N, 7.92. Found: C, 65.48; H, 6.20; N, 7.80. $[\alpha]_D = +9.48$, $c=0.485$ (MeOH)

20

EXAMPLE 89

trans-4-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclohexanol dimaleate

mp 150.5-152° C.

- 25 Analysis calculated for $C_{27}H_{35}FN_3O \cdot 2 C_4H_4O_4 \cdot 0.50 H_2O$: C, 61.94; H, 6.68; N, 6.19. Found: C, 61.67; H, 6.70; N, 6.36.

-56-

EXAMPLE 90

cis-4-[4-(Spiro[cyclohexane-1,1'-[1H]inden]-4-yl)-1-piperazinyl]-2-fluoro-benzonitrile maleate

mp 218.5-219.5° C.

5 Analysis calculated for $C_{25}H_{26}FN_3 \cdot C_4H_4O_4$: C, 69.17; H, 6.00; N, 8.34. Found: C, 68.99; H, 6.02; N, 7.94.

EXAMPLE 91

trans-4-[4-(4'-Bromo-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl)-piperazine-1-yl]-2-fluoro-benzonitrile

10 mp = > 250° C.

1H NMR ($CDCl_3$, 400 MHz) δ 1.57-1.66 (m, 3H), 1.85-2.15 (m, 5H), 2.37 (s, 1H), 2.65-2.68 (m, 4H), 3.34-3.37 (m, 4H), 5.00 (s, 2H), 6.53-6.57 (m, 2H), 7.10-7.16 (m, 2H), 7.36-7.41 (m, 2H).

EXAMPLE 92

15 cis-N-[4-[4-(4-Cyano-3-fluorophenyl)-1-piperazinyl]-2',3'-dihydrospiro[cyclohexane-1,1'-[1H']inden]-3'-yl]-acetamide mesylate (+ enantiomer)

mp = > 250° C.

FW = 446.57 (freebase), API-MS, (M+1) = 447.

20 1H NMR ($CDCl_3$, 400 MHz) δ 1.35-1.45 (m, 3H), 1.51-1.59 (m, 6H), 1.98 (s, 3H), 2.12 (s, 1H), 2.34 (br. s., 1H), 2.52-2.55 (m, 1H), 2.67 (br. s., 4H), 3.35 (br. s., 4H), 5.41-5.47 (m, 1H), 5.97-5.99 (m, 1H), 6.5-6.6 (m, 2H), 7.19-7.35 (m, 5H).

EXAMPLE 93

cis-N-[4-[4-(4-Cyano-3-fluorophenyl)-1-piperazinyl]-2',3'-dihydrospiro[cyclohexane-1,1'-[1H]inden]-3'-yl]-acetamide mesylate (- enantiomer)

25 mp = > 250° C.

FW = 446.57 (freebase), API-MS (M-1) = 445

-57-

EXAMPLE 94

cis-4-[4-Phenyl-1-piperazinyl]-spiro[cyclohexane-1,1'-[1H]inden]-3'(2'H)-one mesylate

mp = > 250°C.

5 FW = 360.50 (freebase), GC-MS t_R = 9.043 min., M^+ = 360.

1H NMR ($CDCl_3$, 400 MHz) δ 1.31-1.34 (m, 2H), 1.57-1.70 (m, 2H), 2.04-2.14 (m, 4H), 2.36 (s, 1H), 2.61 (s, 2H), 2.71 (s, 4H), 3.25 (s, 4H), 6.83-6.87 (m, 1H), 6.94-6.96 (m, 2H), 7.24-7.38 (m, 4H), 7.68 (m, 2H), 7.7 (m, 1H).

EXAMPLE 95

10 trans-3-(4-3'H-Spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-benzonitrile hydrochloride

mp = > 250°C.

FW = 373.50 (freebase), t_R = 9.39 min., GC-MS, M^+ = 373.

15 1H NMR ($CDCl_3$, 400 MHz) δ 1.64-1.76 (m, 2H), 1.94-1.94 (br. s, 4H), 2.02-2.06 (m, 2H), 2.41 (s, 1H), 2.73 (br. s, 4H), 3.27 (br. s., 4H), 5.07 (s, 2H), 7.09 7.14 (m, 3H), 7.26-7.35 (m, 5H).

^{13}C NMR ($CDCl_3$, 75 Mhz) δ 24.79, 33.14, 48.69, 49.70, 59.09, 70.51, 86.77, 112.99, 118.21, 119.44, 119.67, 121.13, 121.32, 122.34, 127.04, 127.40, 129.84, 139.22, 146.24, 151.38.

20

EXAMPLE 96

trans-1-(3-Methoxy-phenyl)-4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazine hydrochloride

mp = > 250°C.

FW=378.52 (freebase), t_R = 8.83min., M^+ = 378.

-58-

^1H NMR (CDCl_3 , 400 MHz) δ 1.63-1.66 (m, 2H), 1.93-2.1 (m, 6H), 2.2 (br. s, 1H), 2.72 (br. s., 4H), 3.24 (br. s., 4H), 3.8 (s, 3H), 5.05 (s, 2H), 6.40-6.57 (m, 3H), 7.12-7.35 (m, 5H).

^{13}C NMR (CDCl_3 , 100 MHz) δ 24.66, 33.27, 49.22, 49.88, 55.10, 59.51, 70.42, 86.69, 102.34, 104.34, 108.70, 121.01, 121.43, 126.99, 127.30, 129.70, 139.11, 152.60, 160.51.

EXAMPLE 97

trans-5-Chloro-2-(4-3'H-spiro[cyclohex-1,1'-isobenzofuran]-4-yl-piperazin-1-yl)-pyrimidine maleate


10 mp 229.5-230° C.

Analysis calculated for $\text{C}_{21}\text{H}_{25}\text{ClN}_4\text{O} \cdot \text{C}_4\text{H}_4\text{O}_4$: C, 59.94; H, 5.83; N, 11.18. Found: C, 59.79; H, 5.79; N, 11.28.

-59-

CLAIMS

1. A compound of the formula



wherein a is oxygen, CH_2 , $\text{C}(\text{CH}_3)_2$, NR^{10} , sulfur, SO or SO_2 ;

b is oxygen, CH_2 , $\text{C}=\text{O}$, $\text{C}=\text{NR}^{11}$, $\text{C}=\text{NOH}$, SO_2 , Sulfur, SO, $\text{C}=\text{NO}(\text{C}_1\text{-C}_5)\text{alkyl}$ or CR^7R^8 ;

- 15 each of R^1 through R^6 is selected, independently, from hydrogen, halo (e.g., chloro, fluoro, bromo or iodo), trifluoromethyl, cyano and hydroxy, or R^7 and R^8 together can be $\text{C}(=\text{O})\text{NH}_2$ or $\text{C}(=\text{O})\text{N}(\text{C}_1\text{-C}_4)\text{alkyl}$, with the proviso that neither R^7 nor R^8 can be halo when a is oxygen, NR^{11} , sulfur, SO or SO_2 ; and

- 20 each of R^{10} and R^{11} is selected, independently, from hydrogen, benzyl and $(\text{C}_1\text{-C}_6)\text{alkyl}$;

and the pharmaceutically acceptable salts of such compounds.

2. A compound according to claim 1, wherein a is oxygen.
3. A compound according to claim 2, wherein b is CH_2 .
4. A compound according to claim 3, wherein R^4 , R^5 and R^6 are hydrogen.

-60-

5. A compound according to claim 4, wherein R^3 is selected from chloro, cyano and fluoro.

6. A compound according to claim 5, wherein R^2 is selected from chloro, cyano and fluoro.

5 7. A pharmaceutical composition for treating or preventing a condition selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal,
10 comprising an amount of a compound according to claim 1 that is effective in treating or preventing such condition, and a pharmaceutical acceptable carrier.

8. A method of treating or preventing a condition selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side
15 effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating or preventing such condition.

9. A pharmaceutical composition for treating or preventing a condition
20 selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, comprising a dopaminergic effective amount of a compound according to claim 1 and
25 a pharmaceutically acceptable carrier.

10. A method of treating or preventing a condition selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia,
30 and nausea, emesis, hyperdermia and amenorrhea in a mammal comprising an

administering to said mammal a dopaminergic effective amount of a compound according to claim 1.

11. A pharmaceutical composition for treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising a dopaminergic effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

12. A method of treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising administering to said mammal a dopaminergic effective amount of a compound according to claim 1.

13. A pharmaceutical composition for treating or preventing a condition selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, comprising a D4 receptor binding effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

14. A method of treating or preventing a condition selected from psychosis, nonorganic psychosis, personality disorders, schizophrenic and schizoaffective disorders, bipolar disorders, dysphoric mania, Parkinson's disease, extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, and nausea, emesis, hyperdermia and amenorrhea in a mammal, comprising administering to said mammal a D4 receptor binding effective amount of a compound according to claim 1.

15. A pharmaceutical composition for treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising a D4 receptor binding effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

-62-

16. A method of treating or preventing a disease or condition, the treatment or prevention of which can be effected or facilitated by altering dopamine mediated neurotransmission in a mammal, comprising administering to said mammal a D4 receptor binding effective amount of a compound according to claim 1.

INTERNATIONAL SEARCH REPORT

Intel. Application No
PCT/IB 97/00978

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D307/94 C07D209/96 C07D295/06 C07D295/08 C07D295/14
C07D333/58 C07D333/50 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 3 932 425 A (D. LEDNICER) 13 January 1976 cited in the application see column 40, line 46 - column 42, line 13 & US 4 025 558 A cited in the application & US 4 010 201 A cited in the application ---</p> <p style="text-align: center;">-/--</p>	<p>1,7,9, 11,13,15</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 October 1997

Date of mailing of the international search report

11. 11. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 97/00978

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	L. L. MARTIN ET AL.: "Synthesis of Spiro[isobenzofuran-1(3H),4'-piperidines] as Potential Central Nervous System Agents. 6. Synthesis, ¹³ C NMR, and Biological Evaluation of cis- and trans-4-Amino-3'-arylspro[cyclohexane-1,1'(3'H)-isobenzofuran] Derivatives" JOURNAL OF MEDICINAL CHEMISTRY, vol. 24, 1981, pages 617-21, XP002044884 cited in the application see table I	1
A	--- W. E. PARHAM ET AL.: "Spiro Piperidines. 1. Synthesis of Spiro[isobenzofuran-1(3H),4'-piperidin[-3-ones, Spiro[isobenzofuran-1(3H),4'-piperidines], and Spiro[isobenzotetrahydrothiophene-1(3H),4'-piperidines]" JOURNAL OF ORGANIC CHEMISTRY, vol. 41, no. 15, 1976, pages 2628-33, XP000569247 cited in the application	1
A	--- US 5 352 678 A (R. J. MATTSON ET AL.) 4 October 1994 cited in the application see claims 1,5	1,7,9,11,13,15
A	--- US 5 403 846 A (J. J. BALDWIN ET AL.) 4 April 1995 cited in the application see claims 1-3	1
A	--- WO 95 30642 A (PHARMACOPEIA, INC.) 16 November 1995 cited in the application see claims 4,11	1
A	--- DE 28 18 329 A (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.) 8 November 1979 see claims 1,2	1
A	--- DE 19 57 490 A (MERCK PATENT GMBH) 16 June 1971 see claim 4	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 97/00978

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT1B 97 00978

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 8,10,12,14,16

because they relate to subject matter not required to be searched by this Authority, namely:

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Remark : Although claims 8, 10, 12, 14, and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. onal Application No

PCT/IB 97/00978

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3932425 A	13-01-76	US 4025558 A US 4010201 A	24-05-77 01-03-77
US 5352678 A	04-10-94	US 5595993 A AT 123774 T CA 2091204 A,C DE 69300192 D EP 0560669 A ES 2076051 T JP 2101094 C JP 6080655 A JP 7110857 B	21-01-97 15-06-95 12-09-93 20-07-95 15-09-93 16-10-95 22-10-96 22-03-94 29-11-95
US 5403846 A	04-04-95	AU 1258295 A WO 9514469 A	13-06-95 01-06-95
WO 9530642 A	16-11-95	AU 2586995 A CA 2189634 A EP 0758313 A	29-11-95 16-11-95 19-02-97
DE 2818329 A	08-11-79	NONE	
DE 1957490 A	16-06-71	AT 298488 A AT 300801 A AT 300802 A AT 300803 A AT 300799 A BE 758919 A CA 954133 A CH 561199 A CH 565173 A CH 561200 A CH 561201 A CH 564008 A CS 162732 B CS 162733 B CS 162734 B CS 162735 B CS 162736 B DK 126044 B	15-04-72 15-07-72 15-07-72 15-07-72 15-07-72 13-05-71 03-09-74 30-04-75 15-08-75 30-04-75 30-04-75 15-07-75 15-07-75 15-07-75 15-07-75 15-07-75 04-06-73

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.

PCT/IB 97/00978

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 1957490 A		FR 2073359 A	01-10-71
		GB 1289209 A	13-09-72
		NL 7015562 A	18-05-71
		SE 370400 B	14-10-74
		US 3721672 A	20-03-73
		ZA 7006933 A	28-07-71
